Compare Moderna, Inc. (MRNA) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sprott Uranium Miners ETF — how do they compare? Moderna, Inc. trades at $60.51 (market cap $24.18B), while Sprott Uranium Miners ETF trades at $55.4. The key difference: Moderna, Inc. is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | URNM | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $81.80 | $83.99 |
52-Week Low | $22.36 | $44.14 |
Enterprise Value | $20.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
URNM trades at $55.50, up 1.65% today, with a bullish technical signal driven by moving averages. Recent news highlights strong nuclear sector tailwinds from AI power demand and government funding, though some articles question miner valuations. Support and resistance cluster tightly around $55-56, indicating potential volatility.
The outlook is positive given nuclear energy's role in AI infrastructure, but risks include uranium price volatility and concentrated miner exposure. Analyst sentiment is mixed, with debates over supply chain positioning versus pure uranium price leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
